<DOC>
	<DOCNO>NCT01733095</DOCNO>
	<brief_summary>Portopulmonary hypertension denotes pulmonary hypertension complicate portal hypertension present approximately 5 % cirrhotic patient . Treatment option include prostanoids , sildenafil , endothelin-receptor antagonist , bosentan ambrisentan . This study investigate safety efficacy ambrisentan portopulmonary hypertension .</brief_summary>
	<brief_title>Ambrisentan Treatment Portopulmonary Hypertension</brief_title>
	<detailed_description>Patients clinically significant PoPH ( rest mean pulmonary arterial pressure &gt; 25 mm Hg , pulmonary vascular resistance &gt; 400 dynes*s*cm-5 ) offer treatment ambrisentan . Patients follow clinically hemodynamically 12 month start treatment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Adult patient portal hypertension , age &gt; 18 year Cirrhosis etiology ; ChildPugh class A B Noncirrhotic portal hypertension ( e.g . chronic portal vein thrombosis ) Informed consent Presence cause pulmonary arterial hypertension History pulmonary embolism myocardial infarction within 6 month study start ChildPugh class C Presence hepatocellular carcinoma Liver transplantation HIV infection Severe obstructive restrictive pulmonary disease ( predict FEV1 VC &lt; 65 % , respectively ) Severe dilate cardiomyopathy ( EF &lt; 50 % ) Latent leftheart insufficiency Pregnancy lactation Esophageal variceal hemorrhage within last 6 month Refractory ascites Hepatorenal syndrome Persistent hepatic encephalopathy &gt; grade 1 Bilirubin &gt; 3.0 mg/dl AST and/or ALT &gt; 3x ULN Creatinine &gt; 2.0 mg/dl Known hypersensitivity ambrisentan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>